Bristol-Myers Squibb

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. 

CEO
Christopher S. Boerner
CEOChristopher S. Boerner
Employees
34,100
Employees34,100
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
1933
Founded1933
Employees
34,100
Employees34,100

BMY Key Statistics

Market cap
113.77B
Market cap113.77B
Price-Earnings ratio
18.59
Price-Earnings ratio18.59
Dividend yield
4.52%
Dividend yield4.52%
Average volume
12.31M
Average volume12.31M
High today
$55.90
High today$55.90
Low today
$54.72
Low today$54.72
Open price
$55.06
Open price$55.06
Volume
9.42M
Volume9.42M
52 Week high
$63.33
52 Week high$63.33
52 Week low
$42.52
52 Week low$42.52

Stock Snapshot

With a market cap of 113.77B, Bristol-Myers Squibb(BMY) trades at $55.81. The stock has a price-to-earnings ratio of 18.59 and currently yields dividends of 4.5%.

As of 2026-02-03, Bristol-Myers Squibb(BMY) stock has fluctuated between $54.72 and $55.90. The current price stands at $55.81, placing the stock +2.0% above today's low and -0.2% off the high.

The Bristol-Myers Squibb(BMY)'s current trading volume is 9.42M, compared to an average daily volume of 12.31M.

In the last year, Bristol-Myers Squibb(BMY) shares hit a 52-week high of $63.33 and a 52-week low of $42.52.

In the last year, Bristol-Myers Squibb(BMY) shares hit a 52-week high of $63.33 and a 52-week low of $42.52.

BMY News

Simply Wall St 3d
Bristol-Myers Squibb Cancer And AI Deals Put Valuation In Focus

Bristol-Myers Squibb, NYSE:BMY, has entered a collaboration with Janux Therapeutics to co-develop a tumor-activated cancer therapy targeting solid tumors. The...

Bristol-Myers Squibb Cancer And AI Deals Put Valuation In Focus
TipRanks 4d
BioNTech and Bristol-Myers Squibb Advance Pumitamig Trial in Aggressive Brain Cancer

Bristol-Myers Squibb Company (BMY), Biontech Se Sponsored Adr (BNTX) announced an update on their ongoing clinical study. Study Overview BioNTech and Bristol-...

Simply Wall St 4d
A Look At Bristol Myers Squibb Valuation After Recent Share Price Momentum

Bristol-Myers Squibb (BMY) is back on many investors’ radar after recent share price moves and fresh scrutiny of its fundamentals, including revenue of US$48.0b...

A Look At Bristol Myers Squibb Valuation After Recent Share Price Momentum

Analyst ratings

60%

of 30 ratings
Buy
36.7%
Hold
60%
Sell
3.3%

More BMY News

TipRanks 5d
Bristol-Myers Squibb Expands Real-World Evidence for Mavacamten in China: What Investors Should Know

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Study Overview Bristol-Myers Squibb is running a single-arm observatio...

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.